Skip to main content

Press releases

28/12/25 - 18:48

Diasorin receives FDA 510(k) clearance and CLIA-waiver for its first assay, the 4-Plex Respiratory Panel, on the LIAISON NES Molecular Diagnostics platform (140.92 KB)
Products Molecular

22/12/25 - 17:25

2026 Annual Corporate Events Calendar (117.34 KB)
Other

22/12/25 - 17:18

Publication of documents for the Shareholders’ Meeting to be held on January 27, 2026 (144.42 KB)
Other

22/12/25 - 14:36

The Board of Directors approved to submit to the Shareholders' Meeting the authorization for the purchase and cancellation of treasury shares for the purpose of shareholder remuneration. Ordinary and extraordinary shareholders' meeting convened. (125.84 KB)
Other

24/11/25 - 11:10

Diasorin submits the LIAISON PLEX Gastrointestinal Flex Assay to the U.S. FDA for 510(k) Clearance (128.44 KB)
Products Molecular

18/11/25 - 6:30

Diasorin, in partnership with QIAGEN, unveils the next generation of the LIAISON QuantiFERON-TB Gold Plus II assay to deliver significant testing productivity and faster results in all Countries accepting the CE mark (147.94 KB)
Products Immunodiagnostic

05/11/25 - 17:46

Diasorin’s Board of Directors approves results for the first 9 months of 2025. FY 2025 Guidance revised (255.77 KB)
Financial Data

31/10/25 - 10:12

Diasorin receives 510(k) clearance for Simplexa COVID-19, Flu A/B & RSV Direct kit on the LIAISON MDX from the U.S. Food and Drug Administration (132.55 KB)
Products Molecular

22/10/25 - 7:41

Diasorin signs a supplier agreement with Quest Diagnostics for the innovative molecular multiplexing platform, LIAISON PLEX (125.42 KB)
Molecular

19/09/25 - 9:34

Diasorin launches LIAISON® TSH-R Ab, an immunodiagnostic assay to improve Graves’ Disease diagnosis, in all countries accepting CE mark (130.17 KB)
Products Immunodiagnostic

08/09/25 - 11:16

New evidence on MeMed BV's role in supporting emergency medicine clinical decisions unveiled at ACEP 2025 (136.64 KB)
Products Immunodiagnostic

31/07/25 - 16:22

Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed (238.17 KB)
Financial Data

02/07/25 - 8:10

Diasorin submits the LIAISON NES® Point-of-Care molecular diagnostics system and 4-plex Respiratory Panel to the FDA for 510(k) Clearance and CLIA Waiver (133.82 KB)
Products Molecular

07/06/25 - 12:25

Diasorin announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (143.05 KB)
Products Molecular

06/05/25 - 17:41

Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance (268.56 KB)
Financial Data

28/04/25 - 16:50

Shareholders' Meeting 2025 (138.81 KB)
Other

18/04/25 - 18:11

Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)
Products

07/04/25 - 13:07

Publication of the lists of candidates for the appointment of the Board Directors, the Board of Statutory Auditors and relevant proposals for resolution. (111.09 KB)
Financial Disclosures

04/04/25 - 0:59

Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999 (125.78 KB)
Other

31/03/25 - 19:36

Adoption of the enhancement of the increased voting rights mechanism: withdrawal exercised by 1.69% of the share capital. Statutory option and pre-emption offer period to start on 31 March 2025. (119.78 KB)
Other

18/03/25 - 11:54

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)
Products Molecular

14/03/25 - 16:29

The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share (239.79 KB)
Financial Data

03/03/25 - 21:19

Registration and publication the minutes of shareholders' meeting. Withdrawal right. (101.04 KB)
Other

03/03/25 - 21:05

Notice to Shareholders - Information regarding the exercise of the withdrawal right (88.54 KB)
Other

28/02/25 - 11:49

The Extraordinary Meeting of Shareholders approves the enhancement of the increased voting rights mechanism (111.6 KB)
Other

27/01/25 - 20:14

Proposal to enhance the increased voting rights mechanism to support the Company's growth strategy, also by external lines, and reward a shareholder base with a long-term investment horizon (126.5 KB)
Other

20/12/12 - 1:00

Shareholders' meeting (55.42 KB)
Financial Data

07/11/12 - 1:00

The BoD approves Q3'12 results (280.42 KB)
Financial Data

03/08/12 - 2:00

The BoD approves H1'12 results (279.41 KB)
Financial Data

30/07/12 - 2:00

DiaSorin in India: JV with Trivitron Healthcare (56.16 KB)
Acquisition / Partnership

27/06/12 - 2:00

Notification of changes in share capital (335.97 KB)
Financial Data

11/05/12 - 2:00

The BoD approves Q1'12 results (122.04 KB)
Financial Data

04/05/12 - 2:00

NorDiag acquisition (88.87 KB)
Acquisition / Partnership

23/04/12 - 2:00

2011 statutory financial statement approval (182.29 KB)
Financial Data

10/04/12 - 2:00

Measles and Mumps IgM on LIAISON (available outside the US and Canada only) (43.59 KB)
Products Immunodiagnostic

02/04/12 - 2:00

Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only) (43.85 KB)
Products Immunodiagnostic

30/03/12 - 2:00

Financial calendar update (176.51 KB)
Financial Data

22/03/12 - 1:00

Stock options to employees (175.38 KB)
Financial Data

12/03/12 - 1:00

Agreement with Sonic Healthcare on Vitamin D (179.85 KB)
Acquisition / Partnership

09/03/12 - 1:00

The BoD approves FY 2011 results (357.11 KB)
Financial Data

07/03/12 - 1:00

Notification of changes in share capital (46.84 KB)
Financial Data

17/02/12 - 1:00

DiaSorin became a member of the ISBT (178.96 KB)
Acquisition / Partnership

09/02/12 - 1:00

Notice of change in share capital (46.97 KB)
Financial Data

02/02/12 - 1:00

FDA clearance for 25 OH Vitamin D on LIAISON (180.35 KB)
Products Immunodiagnostic

27/01/12 - 1:00

2012 Financial calendar update (177.74 KB)
Financial Data

25/01/12 - 1:00

Dividend distribution in June (115.61 KB)
Financial Data

19/01/12 - 1:00

Prize for best Italian Company in R&D in the UK (183.95 KB)
Other

13/01/12 - 1:00

2012 Financial calendar (176.51 KB)
Financial Data

12/01/12 - 1:00

New anti HBs II (available outside the US and Canada only) (196.83 KB)
Products Immunodiagnostic